{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T07:15:52Z","timestamp":1790320552252,"version":"4.1.0"},"reference-count":69,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T00:00:00Z","timestamp":1559001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2019.00109","type":"journal-article","created":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T01:20:28Z","timestamp":1559006428000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":68,"title":["Drugs for Influenza Treatment: Is There Significant News?"],"prefix":"10.3389","volume":"6","author":[{"given":"Nicola","family":"Principi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Camilloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Alunno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Polinori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Argentiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,5,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S0140-6736(17)30129-0","article-title":"Influenza","volume":"390","author":"Paules","year":"2017","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1080\/21645515.2015.1055428","article-title":"Protection of young children from influenza through universal vaccination","volume":"11","author":"Principi","year":"2015","journal-title":"Hum Vaccin Immunother."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000092188.48726.e4","article-title":"Socioeconomic impact of influenza on healthy children and their families","author":"Principi","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1089\/vim.2017.0141","article-title":"Influenza virus: dealing with a drifting and shifting pathogen","volume":"31","author":"Kim","year":"2018","journal-title":"Viral Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/cc8891","article-title":"Bench-to-bedside review: vaccine protection strategies during pandemic flu outbreaks","volume":"14","author":"Chua","year":"2010","journal-title":"Crit Care."},{"key":"B6","doi-asserted-by":"publisher","first-page":"5388","DOI":"10.1016\/j.vaccine.2017.08.034","article-title":"The road to a more effective influenza vaccine: up to date studies and future prospects","volume":"35","author":"Sano","year":"2017","journal-title":"Vaccine"},{"key":"B7","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1080\/21645515.2017.1405188","article-title":"Influenza immunization policies: which could be the main reasons for differences among countries?","volume":"14","author":"Principi","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"B8","unstructured":"European Center for Disease prevention and ControlSeasonal Influenza Vaccination in Europe Vaccination Recommendations and Coverage Rates in the EU Member States for Eight Influenza Seasons 2007\u20132008 to 2014\u20132015"},{"key":"B9","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ijid.2017.10.004","article-title":"Patterns of influenza vaccination coverage in the United States from 2009 to 2015","volume":"65","author":"Chiu","year":"2017","journal-title":"Int J Infect Dis."},{"key":"B10","unstructured":"World Health OrganizationInfluenza (Seasonal)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ccm.2016.11.008","article-title":"Antiviral treatments","volume":"38","author":"Ison","year":"2017","journal-title":"Clin Chest Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"Doc04","DOI":"10.3205\/id000030y","article-title":"Influenza viruses - antiviral therapy and resistance","volume":"5","author":"Duwe","year":"2017","journal-title":"GMS Infect Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1001\/jama.2009.294","article-title":"Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States","volume":"301","author":"Dharan","year":"2009","journal-title":"JAMA"},{"key":"B14","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.antiviral.2009.03.003","article-title":"Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa","volume":"83","author":"Hurt","year":"2009","journal-title":"Antiviral Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jcv.2010.02.019","article-title":"Oseltamivir-induced resistant pandemic A\/H1N1 influenza virus in a child with cystic fibrosis and Pseudomonas aeruginosa infection","volume":"48","author":"Esposito","year":"2010","journal-title":"J Clin Virol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/nyas.12462","article-title":"Continuing challenges in influenza","volume":"1323","author":"Webster","year":"2014","journal-title":"Ann N Y Acad Sci"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1056\/NEJMc1111078","article-title":"Community transmission of oseltamivir-resistant A(H1N1)pdm09 influenza","volume":"365","author":"Hurt","year":"2011","journal-title":"N Engl J Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/irv.12047","article-title":"Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance","volume":"7","author":"McKimm-Breschkin","year":"2013","journal-title":"Influenza Other Respir Viruses."},{"key":"B19","first-page":"1708","article-title":"Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection","volume-title":"N Engl J Med","author":"Bautista","year":"2010"},{"key":"B20","doi-asserted-by":"publisher","first-page":"7524","DOI":"10.1016\/j.vaccine.2011.08.010","article-title":"Seasonal influenza: the burden of disease in children","volume":"29","author":"Fraaij","year":"2011","journal-title":"Vaccine"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1002\/jmv.20951","article-title":"Neuraminidase inhibitor resistance in influenza viruses","volume":"79","author":"Reece","year":"2007","journal-title":"J Med Virol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1586\/17476348.2016.1126182","article-title":"Oseltamivir for influenza infection in children: risks and benefits","volume":"10","author":"Esposito","year":"2016","journal-title":"Expert Rev Respir Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1093\/infdis\/jiw033","article-title":"Benefit of early initiation of influenza antiviral treatment to pregnant women hospitalized with laboratory-confirmed influenza","volume":"214","author":"Oboho","year":"2016","journal-title":"J Infect Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"CD008965","DOI":"10.1002\/14651858.CD008965.pub4","article-title":"Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children","volume":"4","author":"Jefferson","year":"2014","journal-title":"Cochrane Database Syst Rev."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/S0140-6736(14)62449-1","article-title":"Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials","volume":"385","author":"Dobson","year":"2015","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","first-page":"E454","DOI":"10.3390\/v10090454","article-title":"Neuraminidase inhibitors in influenza treatment and prevention. Is it time to call it a day?","volume":"10","author":"Parra-Rojas","year":"2018","journal-title":"Viruses"},{"key":"B27","doi-asserted-by":"publisher","first-page":"j2841","DOI":"10.1136\/bmj.j2841","article-title":"WHO downgrades oseltamivir on drugs list after reviewing evidence","volume":"357","author":"Kmietowicz","year":"2017","journal-title":"BMJ"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1093\/jac\/dkx271","article-title":"Safety and effectiveness of neuraminidase inhibitors for influenza treatment, prophylaxis, and outbreak control: a systematic review of systematic reviews and\/or meta-analyses","volume":"72","author":"Doll","year":"2017","journal-title":"J Antimicrob Chemother."},{"key":"B29","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S2213-2600(14)70041-4","article-title":"Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data","volume":"2","author":"Muthuri","year":"2014","journal-title":"Lancet Resp Med."},{"key":"B30","unstructured":"European Center for Disease Prevention and ControlExpert Opinion on Neuraminidase Inhibitors for the Prevention and Treatment of Influenza. Review of Recent Systematic Reviews and Meta-Analyses"},{"key":"B31","doi-asserted-by":"publisher","first-page":"CD002744","DOI":"10.1002\/14651858.CD002744.pub4","article-title":"Neuraminidase inhibitors for preventing and treating influenza in children (published trials only)","volume":"4","author":"Wang","year":"2012","journal-title":"Cochrane Database Syst Rev."},{"key":"B32","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/infdis\/jis726","article-title":"Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients","volume":"207","author":"Muthuri","year":"2013","journal-title":"J Infect Dis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3851\/IMP3189","article-title":"A meta-analysis of laninamivir octanoate for treatment and prophylaxis of influenza","volume":"23","author":"Higashiguchi","year":"2018","journal-title":"Antivir Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2147\/IDR.S86460","article-title":"Peramivir injection in the treatment of acute influenza: a review of the literature","volume":"9","author":"Wester","year":"2016","journal-title":"Infect Drug Resist."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.3389\/fimmu.2018.01946","article-title":"Treating Influenza Infection, from now and into the future","volume":"9","author":"Davidson","year":"2018","journal-title":"Front Immunol."},{"key":"B36","unstructured":""},{"key":"B37","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1128\/AAC.38.12.2827","article-title":"Inhibition of cap (m7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2,4-dioxobutanoic acid compounds","volume":"38","author":"Tomassini","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"B38","doi-asserted-by":"crossref","first-page":"26","DOI":"10.32607\/20758251-2009-1-2-26-32","article-title":"Influenza virus neuraminidase: structure and function","volume":"1","author":"Shtyrya","year":"2009","journal-title":"Acta Naturae."},{"key":"B39","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.antiviral.2018.10.008","article-title":"In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit","volume":"160","author":"Noshi","year":"2018","journal-title":"Antiviral Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s40261-018-0710-9","article-title":"Safety, tolerability, and pharmacokinetics of the novel anti-influenza agent baloxavir marboxil in healthy adults: phase I study findings","volume":"38","author":"Koshimichi","year":"2018","journal-title":"Clin Drug Investig."},{"key":"B41","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir marboxil for uncomplicated influenza in adults and adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1177\/1060028019826565","article-title":"Baloxavir marboxil: the first cap-dependent endonuclease inhibitor for the treatment of influenza","volume":"53","author":"Yang","year":"2019","journal-title":"Ann Pharmacother."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1800666","DOI":"10.2807\/1560-7917.ES.2019.24.3.1800666","article-title":"Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016\/17 and 2017\/18 seasons","volume":"24","author":"Gubareva","year":"2019","journal-title":"Euro Surveill."},{"key":"B44","doi-asserted-by":"publisher","first-page":"9633","DOI":"10.1038\/s41598-018-27890-4","article-title":"Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil","volume":"8","author":"Omoto","year":"2018","journal-title":"Sci Rep."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1800698","DOI":"10.2807\/1560-7917.ES.2019.24.3.1800698","article-title":"Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018","volume":"24","author":"Takashita","year":"2019","journal-title":"Euro Surveill."},{"key":"B46","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"B47","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antiviral Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(04)16934-1","article-title":"Resistant influenza A viruses in children treated with oseltamivir: descriptive study","volume":"364","author":"Kiso","year":"2004","journal-title":"Lancet."},{"key":"B49","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1086\/596311","article-title":"Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children","volume":"48","author":"Stephenson","year":"2009","journal-title":"Clin Infect Dis."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1128\/AAC.01739-09","article-title":"In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses","volume":"54","author":"Sleeman","year":"2010","journal-title":"Antimicrob Agents Chemother."},{"key":"B51","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1128\/AAC.01051-06","article-title":"Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice","volume":"51","author":"Sidwell","year":"2007","journal-title":"Antimicrob Agents Chemother."},{"key":"B52","doi-asserted-by":"publisher","first-page":"26742","DOI":"10.1038\/srep26742","article-title":"Combinations of oseltamivir and T-705 extend the treatment window for highly pathogenic influenza A(H5N1) virus infection in mice","volume":"6","author":".Marathe","year":"2016","journal-title":"Sci Rep."},{"key":"B53","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1017\/dmp.2014.151","article-title":"Favipiravir: a new medication for the Ebola virus disease pandemic","volume":"9","author":"Nagata","year":"2015","journal-title":"Disaster Med Public Health Prep"},{"key":"B54","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.antiviral.2009.02.198","article-title":"T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections","volume":"82","author":"Furuta","year":"2009","journal-title":"Antiviral Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.antiviral.2018.03.003","article-title":"Favipiravir as a potential countermeasure against neglected and emerging RNA viruses","volume":"153","author":"Delang","year":"2018","journal-title":"Antiviral Res"},{"key":"B56","doi-asserted-by":"publisher","first-page":"6668","DOI":"10.1021\/jm5007275","article-title":"Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2","volume":"57","author":"Clark","year":"2014","journal-title":"J Med Chem."},{"key":"B57","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.antiviral.2016.10.009","article-title":"Activities of JNJ63623872 and oseltamivir against influenza A H1N1pdm and H3N2 virus infections in mice","volume":"136","author":"Smee","year":"2016","journal-title":"Antiviral Res."},{"key":"B58","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3851\/IMP3212","article-title":"Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a Phase IIa, randomized, double-blind, placebo-controlled study","volume":"23","author":"Trevejo","year":"2018","journal-title":"Antivir Ther."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/infdis\/jiy547","article-title":"Phase 2b Study of pimodivir (JNJ-63623872) as monotherapy or in combination with oseltamivir for treatment of acute uncomplicated seasonal iInfluenza A: TOPAZ Trial","volume":"219","author":"Finberg","year":"2018","journal-title":"J Infect Dis."},{"key":"B60","doi-asserted-by":"publisher","first-page":"187ra170","DOI":"10.1126\/scitranslmed.3005996","article-title":"Glycosylations in the globular head of the hemagglutinin protein modulate the virulence and antigenic properties of the H1N1 influenza viruses","volume":"5","author":"Medina","year":"2013","journal-title":"Sci Transl Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1126\/science.1205669","article-title":"A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins","volume":"333","author":"Corti","year":"2011","journal-title":"Science."},{"key":"B62","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nm.3443","article-title":"Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus","volume":"20","author":"Dilillo","year":"2014","journal-title":"in vivo. Nat Med"},{"key":"B63","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1172\/JCI84428","article-title":"Broadly neutralizing antiinfluenza antibodies require Fc receptor engagement for in vivo protection","volume":"126","author":"Dilillo","year":"2016","journal-title":"J Clin Invest"},{"key":"B64","doi-asserted-by":"publisher","first-page":"e01154","DOI":"10.1128\/AAC.01154-17","article-title":"Phase 2 randomized trial of the safety and efficacy of MHAA4549A, a broadly neutralizing monoclonal antibody, in a human influenza A virus challenge model","volume":"61","author":"McBride","year":"2017","journal-title":"Antimicrob Agents Chemother."},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx163.1352","article-title":"A Phase 2a study to evaluate the safety of MEDI8852 in outpatient adults with acute, uncomplicated influenza A","volume":"4","author":"Ali","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"B66","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.ebiom.2018.12.051","article-title":"Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: results from a randomized, double-blind, phase-2, placebo-controlled study","volume":"40","author":"Hershberger","year":"2019","journal-title":"EBioMedicine"},{"key":"B67","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1080\/19420862.2016.1167294","article-title":"Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza A","volume":"8","author":"Gupta","year":"2016","journal-title":"MAbs"},{"key":"B68","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2016.05.073","article-title":"Structure and function analysis of an antibody recognizing all influenza A subtypes","volume":"166","author":"Kallewaard","year":"2016","journal-title":"Cell"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1128\/AAC.02457-15","article-title":"The hemagglutinin stem-binding monoclonal antibody VIS410 controls influenza virus-induced acute respiratory distress syndrome","volume":"60","author":"Baranovich","year":"2016","journal-title":"Antimicrob Agents Chemother."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2019.00109\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T10:08:03Z","timestamp":1574762883000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2019.00109\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,28]]},"references-count":69,"alternative-id":["10.3389\/fmed.2019.00109"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2019.00109","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,28]]},"article-number":"109"}}